hims fda - Search News

Hims, Hers and Ozempic

Hims & Hers can't sell off-brand Ozempic forever, but it can still sell these weight-loss meds

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, the company will soon have to halt sales of its cheaper alternative. That said,

Business Insider · 3h

Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared "aspirational."

AOL · 1h

Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

ConsumerAffairs52m

Hims & Hers withdraws from Wegovy, Ozempic market

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Hims & Hers Health Analyst Sees Buying Opportunity Following Steep Selloff: 'We See No Reason To Change Our View'

Hims & Hers Health Inc. (NYSE: HIMS) shares dropped sharply after the company reported its fourth-quarter earnings. Here's ...

4don MSN

Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

WCPO Cincinnati3h

Hims and Hers likely to stop selling cheaper versions of GLP-1 medications

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

STAT5h

Lilly expands its Zepbound vial offering, as Hims pulls back on semaglutide

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

HIMS Earnings Preview: Will The Stock Rebound After 25% Drop?

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

Hims & Hers Health: Focus On The Future, Not GLP-1s

Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.

Investor's Business Daily on MSN5h

IBD 50's No. 2, Hims & Hers, Crashes 15% Despite Upbeat Earnings

Compounding pharmacy and IBD 50 newcomer Hims & Hers Health reported bullish earnings and sales growth late Monday. But Hims ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results